Overview

In this video, Prof. Jonathan Silverberg discusses the stability and durability of clinical
response with lebrikizumab, an IL-13 inhibitor, compared with IL-13/4 inhibitor
treatment in moderate-to-severe atopic dermatitis. He reviews how targeted IL-13
inhibition supports sustained control of key disease measures, including disease severity
and itch response, supporting maintenance of long-term treatment response in moderate-
to-severe AD.

This Class for

Clinical Pharmacy
Pharmacy
Physician
Resident / Fellow

What I will learn?

● Review the concept of stable, sustained response with lebrikizumab
in moderate-to-severe atopic dermatitis.
● Compare durability of response between IL-13 inhibition and IL-13/4
inhibitor treatment treatment in moderate-to-severe atopic
dermatitis.
● Summarize the clinical evidence supporting maintenance of response
over time.
● Explain how targeted IL-13 inhibition supports stable, long-term
treatment response with lebrikizumab in moderate-to-severe atopic
dermatitis.

Disclaimer

This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
(This information/content is intended to Health Care Providers only)

For adverse events and safety reporting: email: [email protected]

24 /7 mobile: +966 567 868 843, Working hours Tel: +966 11 461 7800 , Ext: 1

For Lilly product information: email: [email protected]

For further information, please contact:

Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: [email protected]

PP-LK-SA-0196

Content